You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameLurasidone
Accession NumberDB08815
TypeSmall Molecule
GroupsApproved
DescriptionLurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. (Wikipedia)
Structure
Thumb
Synonyms
Lurasidona
Lurasidonum
External Identifiers
  • SM-13496
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Latudatablet80 mgoralSunovion Pharmaceuticals Canada Inc2012-09-05Not applicableCanada
Latudatablet, film coated20 mg/1oralSunovion Pharmaceuticals Inc.2011-12-07Not applicableUs
Latudatablet, film coated120 mg/1oralSunovion Pharmaceuticals Inc.2012-04-26Not applicableUs
Latudatablet120 mgoralSunovion Pharmaceuticals Canada Inc2012-09-06Not applicableCanada
Latudatablet, film coated40 mg/1oralSunovion Pharmaceuticals Inc.2010-10-28Not applicableUs
Latudatablet, film coated40 mg/1oralAvera Mc Kennan Hospital2015-03-02Not applicableUs
Latudatablet60 mgoralSunovion Pharmaceuticals Canada Inc2014-03-14Not applicableCanada
Latudatablet, film coated60 mg/1oralSunovion Pharmaceuticals Inc.2013-07-12Not applicableUs
Latudatablet40 mgoralSunovion Pharmaceuticals Canada Inc2012-09-06Not applicableCanada
Latudatablet20 mgoralSunovion Pharmaceuticals Canada Inc2014-04-09Not applicableCanada
Latudatablet, film coated80 mg/1oralSunovion Pharmaceuticals Inc.2010-10-28Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Lurasidone Hydrochloride
Thumb
  • InChI Key: NEKCRUIRPWNMLK-SCIYSFAVSA-N
  • Monoisotopic Mass: 528.232574845
  • Average Mass: 529.137
DBSALT000113
Categories
UNII22IC88528T
CAS number367514-87-2
WeightAverage: 492.676
Monoisotopic: 492.255897106
Chemical FormulaC28H36N4O2S
InChI KeyInChIKey=PQXKDMSYBGKCJA-CVTJIBDQSA-N
InChI
InChI=1S/C28H36N4O2S/c33-27-24-18-9-10-19(15-18)25(24)28(34)32(27)17-21-6-2-1-5-20(21)16-30-11-13-31(14-12-30)26-22-7-3-4-8-23(22)35-29-26/h3-4,7-8,18-21,24-25H,1-2,5-6,9-17H2/t18-,19+,20-,21-,24+,25-/m0/s1
IUPAC Name
(1R,2S,6R,7S)-4-{[(1R,2R)-2-{[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]methyl}cyclohexyl]methyl}-4-azatricyclo[5.2.1.0²,⁶]decane-3,5-dione
SMILES
O=C1[[email protected]]2[C@@H]3CC[C@@H](C3)[[email protected]]2C(=O)N1C[C@@H]1CCCC[[email protected]]1CN1CCN(CC1)C1=NSC2=CC=CC=C12
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazinanes
Sub ClassPiperazines
Direct ParentN-arylpiperazines
Alternative Parents
Substituents
  • N-arylpiperazine
  • Norbornane monoterpenoid
  • Monoterpenoid
  • Isoindolone
  • Aromatic monoterpenoid
  • Isoindole or derivatives
  • Isoindoline
  • 1,2-benzothiazole
  • Dialkylarylamine
  • N-alkylpiperazine
  • Dicarboximide
  • Imidolactam
  • Benzenoid
  • N-alkylpyrrolidine
  • 2-pyrrolidone
  • Pyrrolidone
  • Carboxylic acid imide, n-substituted
  • Heteroaromatic compound
  • Thiazole
  • Pyrrolidine
  • Carboxylic acid imide
  • Azole
  • Tertiary aliphatic amine
  • Tertiary amine
  • Lactam
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationTreatment of schizophrenia.
PharmacodynamicsLurasidone is a benzothiazol derivative that is an antagonist and binds with high affinity to Dopamine-2 (D2) (Ki = 0.994 nM), 5-HT2A (Ki = 0.47 nM) receptors, and 5-HT7 receptors (Ki = 0.495 nM). It also binds with moderate affinity to alpha-2C adrenergic receptors (Ki = 10.8 nM) and is a partial agonist at 5-HT1A receptors (Ki = 6.38 nM). Its actions on histaminergic and muscarinic receptors are negligible.
Mechanism of actionLurasidone is an atypical antipsychotic that is a D2 and 5-HT2A (mixed serotonin and dopamine activity) to improve cognition. It is thought that antagonism of serotonin receptors can improve negative symptoms of psychoses and reduce the extrapyramidal side effects that are often associated with typical antipsychotics.
Related Articles
AbsorptionLurasidone is readily absorbed and quickly reaches maximal concentrations (Cmax) within 1-4 hours. When taken with food, there is a two-fold increase in exposure and time to maximal concentration is increased by 0.5-1.5 hours. This occurs regardless of fat or caloric content. Bioavailability = 9-19%.
Volume of distribution

6173 L

Protein binding~99% bound to serum proteins.
Metabolism

Lurasidone is metabolized by CYP3A4 in which its major active metabolite is referred to as ID-14283 (25% of parent exposure). Its two minor metabolites are referred to as ID14326 and ID11614 which make up 3% and 1% of parent exposure respectively. Its two non-active metabolites are referred to as ID-20219 and ID-20220.

SubstrateEnzymesProduct
Lurasidone
Not Available
ID11614Details
Lurasidone
Not Available
ID14326Details
Route of eliminationUrine (~9%) and feces (~80%)
Half life40 mg dose= 18 hours 120 mg - 160 mg dose = 29-37 hours
Clearance

3902 mL/min

ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9907
Caco-2 permeable+0.5257
P-glycoprotein substrateSubstrate0.6029
P-glycoprotein inhibitor IInhibitor0.6713
P-glycoprotein inhibitor IIInhibitor0.73
Renal organic cation transporterInhibitor0.5487
CYP450 2C9 substrateNon-substrate0.7897
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.5922
CYP450 1A2 substrateNon-inhibitor0.677
CYP450 2C9 inhibitorInhibitor0.6714
CYP450 2D6 inhibitorNon-inhibitor0.8292
CYP450 2C19 inhibitorInhibitor0.7439
CYP450 3A4 inhibitorNon-inhibitor0.7835
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8126
Ames testNon AMES toxic0.6477
CarcinogenicityNon-carcinogens0.8986
BiodegradationNot ready biodegradable0.9959
Rat acute toxicity2.4051 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6636
hERG inhibition (predictor II)Inhibitor0.5858
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Tabletoral120 mg
Tabletoral20 mg
Tabletoral40 mg
Tabletoral60 mg
Tabletoral80 mg
Tablet, film coatedoral120 mg/1
Tablet, film coatedoral20 mg/1
Tablet, film coatedoral40 mg/1
Tablet, film coatedoral60 mg/1
Tablet, film coatedoral80 mg/1
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5532372 No1998-07-022018-07-02Us
US8729085 No2006-05-262026-05-26Us
US8883794 No2006-05-262026-05-26Us
US9174975 No2006-06-252026-06-25Us
US9259423 No2011-05-232031-05-23Us
USRE45573 No2005-06-232025-06-23Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.00789 mg/mLALOGPS
logP5.25ALOGPS
logP4.56ChemAxon
logS-4.8ALOGPS
pKa (Strongest Basic)8.5ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area56.75 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity139.33 m3·mol-1ChemAxon
Polarizability56.2 Å3ChemAxon
Number of Rings7ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General References
  1. George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA: Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509. doi: 10.1007/s00228-013-1498-4. Epub 2013 Apr 2. [PubMed:23545936 ]
  2. Tarazi FI, Stahl SM: Iloperidone, asenapine and lurasidone: a primer on their current status. Expert Opin Pharmacother. 2012 Sep;13(13):1911-22. doi: 10.1517/14656566.2012.712114. Epub 2012 Jul 31. [PubMed:22849428 ]
External Links
ATC CodesN05AE05
AHFS Codes
  • 28:16.08.04
PDB EntriesNot Available
FDA labelDownload (452 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetamineLurasidone may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineLurasidone may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Lurasidone.
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Lurasidone.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Lurasidone.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Lurasidone.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Lurasidone.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Lurasidone.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Lurasidone.
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Lurasidone.
AlfaxaloneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Lurasidone.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Lurasidone.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Lurasidone.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Lurasidone.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Lurasidone.
AmiodaroneThe serum concentration of Lurasidone can be increased when it is combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Lurasidone is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Lurasidone.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Lurasidone.
AmoxapineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Lurasidone is combined with Amperozide.
AmphetamineLurasidone may decrease the stimulatory activities of Amphetamine.
AprepitantThe serum concentration of Lurasidone can be increased when it is combined with Aprepitant.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Lurasidone.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Lurasidone.
ArticaineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Lurasidone.
AtazanavirThe serum concentration of Lurasidone can be increased when it is combined with Atazanavir.
AtomoxetineThe metabolism of Lurasidone can be decreased when combined with Atomoxetine.
AzaperoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Azaperone.
AzelastineLurasidone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Lurasidone.
BaclofenThe risk or severity of adverse effects can be increased when Lurasidone is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Lurasidone.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Lurasidone.
BenzphetamineLurasidone may decrease the stimulatory activities of Benzphetamine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Lurasidone.
BexaroteneThe serum concentration of Lurasidone can be decreased when it is combined with Bexarotene.
BoceprevirThe serum concentration of Lurasidone can be increased when it is combined with Boceprevir.
BortezomibThe metabolism of Lurasidone can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Lurasidone can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Lurasidone is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.
BrimonidineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Lurasidone.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Lurasidone.
BrompheniramineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Lurasidone is combined with Brotizolam.
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Lurasidone.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Lurasidone.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Lurasidone.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Lurasidone.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Lurasidone.
ButacaineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Lurasidone is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Lurasidone is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Lurasidone.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Lurasidone.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Lurasidone.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Lurasidone.
CarbamazepineThe serum concentration of Lurasidone can be decreased when it is combined with Carbamazepine.
CarbamazepineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Carbamazepine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Lurasidone.
CarisoprodolThe risk or severity of adverse effects can be increased when Lurasidone is combined with Carisoprodol.
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Lurasidone.
CeritinibThe serum concentration of Lurasidone can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Lurasidone.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Lurasidone.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Lurasidone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Lurasidone.
ChlorphenamineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Chlorphenamine.
ChlorphentermineLurasidone may decrease the stimulatory activities of Chlorphentermine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Lurasidone.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Lurasidone.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Lurasidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Chlorzoxazone.
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Lurasidone.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Lurasidone.
CitalopramThe risk or severity of adverse effects can be increased when Lurasidone is combined with Citalopram.
ClarithromycinThe serum concentration of Lurasidone can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Lurasidone can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Lurasidone is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Lurasidone is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Lurasidone.
ClomipramineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Lurasidone is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Lurasidone.
ClotrimazoleThe metabolism of Lurasidone can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Lurasidone.
CobicistatThe serum concentration of Lurasidone can be increased when it is combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Lurasidone.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Lurasidone.
ConivaptanThe serum concentration of Lurasidone can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Lurasidone can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Lurasidone.
CyclosporineThe metabolism of Lurasidone can be decreased when combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Cyproheptadine.
DabrafenibThe serum concentration of Lurasidone can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Lurasidone.
DapoxetineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Dapoxetine.
DarunavirThe serum concentration of Lurasidone can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Lurasidone can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Lurasidone can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Lurasidone can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Lurasidone.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Lurasidone.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Lurasidone.
DesloratadineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Desloratadine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Lurasidone.
DetomidineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Detomidine.
DexamethasoneThe serum concentration of Lurasidone can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Lurasidone.
DextroamphetamineLurasidone may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Lurasidone.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Lurasidone.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Lurasidone.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Lurasidone.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Lurasidone.
DifenoxinThe risk or severity of adverse effects can be increased when Lurasidone is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Lurasidone.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Lurasidone.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Lurasidone.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Lurasidone.
DiltiazemThe metabolism of Lurasidone can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Lurasidone is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Lurasidone.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Lurasidone.
DisopyramideLurasidone may increase the QTc-prolonging activities of Disopyramide.
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Lurasidone.
DopamineDopamine may increase the hypotensive activities of Lurasidone.
DoramectinThe risk or severity of adverse effects can be increased when Lurasidone is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Lurasidone.
DoxycyclineThe metabolism of Lurasidone can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.
DoxylamineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Lurasidone is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.
DronedaroneThe metabolism of Lurasidone can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Lurasidone.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Lurasidone.
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Lurasidone.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Lurasidone.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Lurasidone.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Lurasidone.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Lurasidone.
EfavirenzThe serum concentration of Lurasidone can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Lurasidone is combined with Efavirenz.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Lurasidone.
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Lurasidone.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Lurasidone.
EntacaponeThe risk or severity of adverse effects can be increased when Lurasidone is combined with Entacapone.
EnzalutamideThe serum concentration of Lurasidone can be decreased when it is combined with Enzalutamide.
EpinephrineEpinephrine may increase the hypotensive activities of Lurasidone.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Lurasidone.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Lurasidone.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Lurasidone.
ErythromycinThe metabolism of Lurasidone can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Lurasidone is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Lurasidone can be decreased when it is combined with Eslicarbazepine acetate.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Lurasidone.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Lurasidone.
EthanolLurasidone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Lurasidone.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lurasidone.
EthosuximideThe risk or severity of adverse effects can be increased when Lurasidone is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Lurasidone is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Lurasidone.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Lurasidone.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Lurasidone.
EtidocaineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Lurasidone is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Lurasidone.
EtoperidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Lurasidone.
EtravirineThe serum concentration of Lurasidone can be decreased when it is combined with Etravirine.
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Lurasidone.
EzogabineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Lurasidone is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Lurasidone.
FenfluramineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Lurasidone.
FexofenadineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Fexofenadine.
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Lurasidone.
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Lurasidone.
FluconazoleThe metabolism of Lurasidone can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Lurasidone.
FlunarizineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Lurasidone.
FluoxetineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Lurasidone.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Lurasidone.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Lurasidone.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Lurasidone.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Lurasidone is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Fluvoxamine.
FosamprenavirThe metabolism of Lurasidone can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Lurasidone can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Lurasidone can be decreased when it is combined with Fosphenytoin.
FosphenytoinThe risk or severity of adverse effects can be increased when Lurasidone is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Lurasidone.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Lurasidone.
Fusidic AcidThe serum concentration of Lurasidone can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Lurasidone.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Lurasidone is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Lurasidone.
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Lurasidone.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Lurasidone.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Lurasidone.
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Lurasidone.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Lurasidone.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Lurasidone.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Lurasidone.
GuanfacineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Lurasidone.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Lurasidone.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Lurasidone.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Lurasidone.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Lurasidone.
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Lurasidone.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Lurasidone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Lurasidone.
Hydroxyamphetamine hydrobromideLurasidone may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.
HydroxyzineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Hydroxyzine.
IdelalisibThe serum concentration of Lurasidone can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Iloperidone.
ImatinibThe metabolism of Lurasidone can be decreased when combined with Imatinib.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Lurasidone.
IndalpineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Indalpine.
IndinavirThe serum concentration of Lurasidone can be increased when it is combined with Indinavir.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Lurasidone.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Lurasidone.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Lurasidone.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Lurasidone.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Lurasidone.
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Lurasidone.
IsavuconazoniumThe metabolism of Lurasidone can be decreased when combined with Isavuconazonium.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Lurasidone.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Lurasidone.
IsradipineThe metabolism of Lurasidone can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Lurasidone can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Lurasidone can be increased when it is combined with Ivacaftor.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Lurasidone.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Lurasidone.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Lurasidone.
KetoconazoleThe serum concentration of Lurasidone can be increased when it is combined with Ketoconazole.
LamotrigineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Lurasidone is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Lurasidone.
LevocabastineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Lurasidone is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Lurasidone.
LevomilnacipranThe risk or severity of adverse effects can be increased when Lurasidone is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Lurasidone.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Lurasidone.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Lurasidone.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Lurasidone.
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Lurasidone.
LisdexamfetamineLurasidone may decrease the stimulatory activities of Lisdexamfetamine.
LithiumLithium may increase the neurotoxic activities of Lurasidone.
LithiumThe risk or severity of adverse effects can be increased when Lurasidone is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Lurasidone is combined with Lofentanil.
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Lurasidone.
LopinavirThe serum concentration of Lurasidone can be increased when it is combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Lurasidone.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Lurasidone.
LovastatinThe metabolism of Lurasidone can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Lurasidone.
Lu AA21004The risk or severity of adverse effects can be increased when Lurasidone is combined with Lu AA21004.
LuliconazoleThe serum concentration of Lurasidone can be increased when it is combined with Luliconazole.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Lurasidone is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Lurasidone.
MeclizineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Lurasidone.
MelperoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Melperone.
MephentermineLurasidone may decrease the stimulatory activities of Mephentermine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Lurasidone.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Lurasidone.
MequitazineLurasidone may increase the arrhythmogenic activities of Mequitazine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Lurasidone.
MetaxaloneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Metaxalone.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Lurasidone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Lurasidone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Lurasidone.
MethamphetamineLurasidone may decrease the stimulatory activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Lurasidone.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Lurasidone.
MethocarbamolThe risk or severity of adverse effects can be increased when Lurasidone is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Lurasidone.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Lurasidone.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Lurasidone.
MethsuximideThe risk or severity of adverse effects can be increased when Lurasidone is combined with Methsuximide.
MethylphenidateThe risk or severity of adverse effects can be increased when Lurasidone is combined with Methylphenidate.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Lurasidone.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Lurasidone.
MetyrosineLurasidone may increase the sedative activities of Metyrosine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Lurasidone.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Lurasidone.
MifepristoneThe metabolism of Lurasidone can be decreased when combined with Mifepristone.
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Lurasidone.
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Lurasidone.
MilnacipranThe risk or severity of adverse effects can be increased when Lurasidone is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.
MirtazapineLurasidone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Lurasidone.
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Lurasidone.
MitotaneThe serum concentration of Lurasidone can be decreased when it is combined with Mitotane.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Lurasidone.
ModafinilThe serum concentration of Lurasidone can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Lurasidone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Lurasidone.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.
NabiloneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Nabilone.
NafcillinThe serum concentration of Lurasidone can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Lurasidone.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Lurasidone.
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Lurasidone.
NefazodoneThe serum concentration of Lurasidone can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Lurasidone can be increased when it is combined with Nelfinavir.
NetupitantThe serum concentration of Lurasidone can be increased when it is combined with Netupitant.
NevirapineThe serum concentration of Lurasidone can be decreased when it is combined with Nevirapine.
NilotinibThe metabolism of Lurasidone can be decreased when combined with Nilotinib.
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Lurasidone.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Lurasidone.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Lurasidone.
NormethadoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Lurasidone.
OlanzapineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Olanzapine.
OlaparibThe metabolism of Lurasidone can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Lurasidone.
OpiumThe risk or severity of adverse effects can be increased when Lurasidone is combined with Opium.
OrphenadrineLurasidone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Lurasidone.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Lurasidone.
OsimertinibThe serum concentration of Lurasidone can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Lurasidone.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Lurasidone.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Lurasidone.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Lurasidone.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Lurasidone.
PalbociclibThe serum concentration of Lurasidone can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Lurasidone.
ParaldehydeLurasidone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Lurasidone.
ParoxetineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Lurasidone.
PentobarbitalThe serum concentration of Lurasidone can be decreased when it is combined with Pentobarbital.
PentobarbitalThe risk or severity of adverse effects can be increased when Lurasidone is combined with Pentobarbital.
PerampanelThe risk or severity of adverse effects can be increased when Lurasidone is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Lurasidone is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Lurasidone.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Lurasidone.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Lurasidone.
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Lurasidone.
PhenobarbitalThe serum concentration of Lurasidone can be decreased when it is combined with Phenobarbital.
PhenobarbitalThe risk or severity of adverse effects can be increased when Lurasidone is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Lurasidone is combined with Phenoxyethanol.
PhentermineLurasidone may decrease the stimulatory activities of Phentermine.
PhenytoinThe serum concentration of Lurasidone can be decreased when it is combined with Phenytoin.
PhenytoinThe risk or severity of adverse effects can be increased when Lurasidone is combined with Phenytoin.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Lurasidone.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Lurasidone.
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Lurasidone.
PipamperoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Lurasidone is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Lurasidone is combined with Pomalidomide.
PosaconazoleThe serum concentration of Lurasidone can be increased when it is combined with Posaconazole.
PramipexoleLurasidone may increase the sedative activities of Pramipexole.
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Lurasidone.
PramocaineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Lurasidone.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Lurasidone.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Lurasidone.
PrimidoneThe serum concentration of Lurasidone can be decreased when it is combined with Primidone.
PrimidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Primidone.
ProcainamideLurasidone may increase the QTc-prolonging activities of Procainamide.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Lurasidone.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Lurasidone.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Lurasidone.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Lurasidone.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Lurasidone.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Lurasidone.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Lurasidone.
PropoxycaineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Lurasidone.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Lurasidone.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Lurasidone.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Lurasidone.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Lurasidone.
QuinidineLurasidone may increase the QTc-prolonging activities of Quinidine.
RamelteonThe risk or severity of adverse effects can be increased when Lurasidone is combined with Ramelteon.
RanolazineThe metabolism of Lurasidone can be decreased when combined with Ranolazine.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Lurasidone.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Lurasidone.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Lurasidone.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Lurasidone.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Lurasidone.
RifabutinThe serum concentration of Lurasidone can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Lurasidone can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Lurasidone can be decreased when it is combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Lurasidone.
RitonavirThe serum concentration of Lurasidone can be increased when it is combined with Ritonavir.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Lurasidone.
RomifidineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Romifidine.
RopiniroleLurasidone may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Lurasidone.
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Lurasidone.
RotigotineLurasidone may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Lurasidone.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Lurasidone.
SaquinavirThe serum concentration of Lurasidone can be increased when it is combined with Saquinavir.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Lurasidone.
ScopolamineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Lurasidone.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Lurasidone.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Lurasidone.
SertralineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Lurasidone.
SildenafilThe metabolism of Lurasidone can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Lurasidone can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Lurasidone can be increased when it is combined with Simeprevir.
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Lurasidone.
Sodium oxybateThe risk or severity of adverse effects can be increased when Lurasidone is combined with Sodium oxybate.
St. John's WortThe serum concentration of Lurasidone can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Lurasidone is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Lurasidone.
SulfisoxazoleThe metabolism of Lurasidone can be decreased when combined with Sulfisoxazole.
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Lurasidone.
SulpirideThe risk or severity of adverse effects can be increased when Lurasidone is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Lurasidone.
SuvorexantThe risk or severity of adverse effects can be increased when Lurasidone is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Lurasidone.
TasimelteonThe risk or severity of adverse effects can be increased when Lurasidone is combined with Tasimelteon.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Lurasidone.
TelaprevirThe serum concentration of Lurasidone can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Lurasidone can be increased when it is combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Lurasidone.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Lurasidone.
TetracaineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Lurasidone.
ThalidomideLurasidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Lurasidone.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Lurasidone.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Lurasidone.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Lurasidone.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Lurasidone.
TiagabineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Tiagabine.
TiclopidineThe metabolism of Lurasidone can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Tiletamine.
TizanidineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Tizanidine.
TocilizumabThe serum concentration of Lurasidone can be decreased when it is combined with Tocilizumab.
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Lurasidone.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Lurasidone.
TolcaponeThe risk or severity of adverse effects can be increased when Lurasidone is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when Lurasidone is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Lurasidone.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Lurasidone.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Lurasidone.
TrazodoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Lurasidone.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Lurasidone.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Lurasidone.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Lurasidone.
TriprolidineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Triprolidine.
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Lurasidone.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Lurasidone.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Lurasidone.
VerapamilThe metabolism of Lurasidone can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Lurasidone is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Vilazodone.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Lurasidone.
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Lurasidone.
VoriconazoleThe serum concentration of Lurasidone can be increased when it is combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Lurasidone.
ZiconotideThe risk or severity of adverse effects can be increased when Lurasidone is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Zimelidine.
ZiprasidoneThe metabolism of Lurasidone can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Lurasidone is combined with Zolazepam.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Lurasidone.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Lurasidone.
ZonisamideThe risk or severity of adverse effects can be increased when Lurasidone is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Lurasidone.
ZotepineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Lurasidone.
Food Interactions
  • When taken with food, there is a two-fold increase in exposure and time to maximal concentration is increased by 0.5-1.5 hours.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA: Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509. doi: 10.1007/s00228-013-1498-4. Epub 2013 Apr 2. [PubMed:23545936 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA: Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509. doi: 10.1007/s00228-013-1498-4. Epub 2013 Apr 2. [PubMed:23545936 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.
Gene Name:
HTR7
Uniprot ID:
P34969
Molecular Weight:
53554.43 Da
References
  1. George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA: Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509. doi: 10.1007/s00228-013-1498-4. Epub 2013 Apr 2. [PubMed:23545936 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA: Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509. doi: 10.1007/s00228-013-1498-4. Epub 2013 Apr 2. [PubMed:23545936 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name:
ADRA2C
Uniprot ID:
P18825
Molecular Weight:
49521.585 Da
References
  1. George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA: Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509. doi: 10.1007/s00228-013-1498-4. Epub 2013 Apr 2. [PubMed:23545936 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Tarazi FI, Stahl SM: Iloperidone, asenapine and lurasidone: a primer on their current status. Expert Opin Pharmacother. 2012 Sep;13(13):1911-22. doi: 10.1517/14656566.2012.712114. Epub 2012 Jul 31. [PubMed:22849428 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA: Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509. doi: 10.1007/s00228-013-1498-4. Epub 2013 Apr 2. [PubMed:23545936 ]
Comments
comments powered by Disqus
Drug created on July 24, 2011 11:04 / Updated on September 25, 2016 02:50